Cardiovascular Systems to Webcast Fiscal 2013 Fourth-Quarter Earnings Conference Call Wednesday, August 7
July 31 2013 - 12:16PM
Business Wire
Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII) will host a
live webcast of its fiscal 2013 fourth-quarter conference call on
Wednesday, Aug. 7, 2013, at 3:45 p.m. CT (4:45 p.m. ET). David
Martin, president and chief executive officer, and Larry Betterley,
chief financial officer, will discuss the company’s results for its
fiscal fourth quarter ended June 30, 2013, and its financial
outlook. The company will issue a post-market earnings release
prior to the call on Aug. 7.
To access the live webcast, go to the investor section of the
company’s website, www.csi360.com, on the day of the conference
call and click on the webcast icon. A webcast replay will be
available beginning at 5:45 p.m. CT the same day.
To participate in the conference call, dial (888) 679-8034 and
enter 39331740. Please dial in at least 10 minutes prior to the
call. To pre-register for the call, log on to the following
website:
https://www.theconferencingservice.com/prereg/key.process?key=PLFRANHTW.
When joining the call, pre-registered participants can enter their
PIN code, and other participants can press *0 to reach the
operator, or wait on the line for operator assistance.
If you do not have access to the Internet and want to listen to
an audio replay of the conference call, dial (888) 286-8010 and
enter access number 41201456. The audio replay will be available
beginning at 5:45 p.m. CT on Wednesday, Aug. 7, 2013, through 11
p.m. CT on Wednesday, Aug. 14, 2013.
About Cardiovascular Systems, Inc.Cardiovascular Systems,
Inc., based in St. Paul, Minn., is a medical device company focused
on developing and commercializing innovative solutions for treating
vascular and coronary disease. The company’s Orbital Atherectomy
Systems treat calcified and fibrotic plaque in arterial vessels
throughout the leg in a few minutes of treatment time, and address
many of the limitations associated with existing surgical, catheter
and pharmacological treatment alternatives. The U.S. FDA granted
510(k) clearance for the use of the Diamondback Orbital Atherectomy
System in August 2007. To date, nearly 110,000 of CSI’s devices
have been sold to leading institutions across the United States.
CSI has also completed its ORBIT II Investigational Device
Exemption clinical trial to evaluate the safety and effectiveness
of its orbital technology in treating coronary arteries. The
coronary system is limited by federal law to investigational use
and is currently not commercially available in the United
States.
For more information, visit the company’s website at
www.csi360.com.
Cardiovascular Systems (NASDAQ:CSII)
Historical Stock Chart
From Jun 2024 to Jul 2024
Cardiovascular Systems (NASDAQ:CSII)
Historical Stock Chart
From Jul 2023 to Jul 2024